0
0
A recent study, known as the D-Lay MS trial and published in the Journal of the American Medical Association (JAMA), has demonstrated that administering high doses of vitamin D significantly reduces disease activity in patients with clinically isolated syndrome (CIS), a condition often preceding multiple sclerosis (MS).
This randomized, placebo-controlled trial involved 316 participants across 36 centers in France. Patients receiving high-dose vitamin D—100,000 international units every two weeks—showed a reduction in MRI-detected disease activity, with 57.1% experiencing such activity compared to 65.3% in the placebo group. Additionally, fewer new lesions were observed in the vitamin D group (46.2%) versus the placebo group (59.2%). However, relapse rates did not differ significantly between the two groups.
These findings suggest that high-dose vitamin D may offer benefits in managing early MS stages. Further research is needed to fully understand its potential as an adjunct therapy.
Disclaimer: This article is based on information from eMediNexus and the referenced study. It is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making any changes to your treatment regimen.
